Zenas Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$5.62next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Investments Quarterly718.5MTarget: Sufficient to fund operations into 2029
Quarterly Net Loss Quarterly-81MTarget: Manageable cash burn aligned with clinical milestones
Quarterly Research and Development (R&D) Expenses Quarterly60.4MTarget: Efficient allocation to late-stage clinical trials
Watch Items
- FDA BLA Review and Approval of Obexelimab in IgG4-RDTrigger: FDA acceptance of BLA filing and PDUFA date assignmentAction: Prepare commercial launch infrastructure and scale up medical affairs
- EMA MAA Submission of Obexelimab in IgG4-RDTrigger: Submission of Marketing Authorization Application in H2 2026Action: Coordinate with European regulatory consultants and prepare for EMA review
- Topline Results of Phase 2 SunStone Trial of Obexelimab in SLETrigger: Data readout expected in Q4 2026Action: Analyze efficacy/safety signals to determine Phase 3 progression strategy
- Initial Clinical Data for ZB021 (Oral IL-17AA/AF Inhibitor)Trigger: Phase 1 trial data readout expected by year-end 2026Action: Evaluate safety, tolerability, and pharmacokinetics to plan Phase 2 trials
Research as of 20 Jun 2026